Scholar Rock (SRRK) Stock Rating Upgraded by Zacks Investment Research

Scholar Rock (NASDAQ:SRRK) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday.

According to Zacks, “Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company’s product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States. “

NASDAQ SRRK traded up $0.43 during mid-day trading on Thursday, reaching $23.86. 24,084 shares of the stock were exchanged, compared to its average volume of 64,807. Scholar Rock has a one year low of $13.09 and a one year high of $27.02.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Wednesday, August 8th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.85). On average, research analysts predict that Scholar Rock will post -4.5 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in SRRK. FMR LLC bought a new position in Scholar Rock during the second quarter worth $54,625,000. Redmile Group LLC bought a new position in Scholar Rock during the second quarter worth $27,306,000. Victory Capital Management Inc. bought a new position in Scholar Rock during the second quarter worth $1,475,000. Millennium Management LLC bought a new position in Scholar Rock during the second quarter worth $1,349,000. Finally, Marshall Wace LLP bought a new position in Scholar Rock during the second quarter worth $1,216,000. 48.37% of the stock is owned by institutional investors and hedge funds.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of various medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company is developing its lead antibody product candidate, SRK-015, a first-in-class inhibitor of the activation of myostatin that is in clinical development stage for the treatment of spinal muscular atrophy.

Recommended Story: What is a stock buyback?

Get a free copy of the Zacks research report on Scholar Rock (SRRK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply